Clinical Trial Update: Expansion Trial for Axitinib In Head And Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 expansion trial of axitinib in head and neck squamous cell carcinoma has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2021-05-05